New treatment of acute myeloid leukemia achieves remarkable results in a disease formerly with little hope
(Monash University) A new Australian drug trial has achieved a remarkable result, clearing the bone marrow of leukemia in almost 60 percent of patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 20, 2019 Category: International Medicine & Public Health Source Type: news

Epigenetic protein could be new therapeutic target in acute myeloid leukemia
(Rockefeller University Press) British researchers have discovered that an epigenetic protein called EZH2 delays the development of acute myeloid leukemia (AML) but then switches sides once the disease is established to help maintain tumor growth. The study, which will be published March 19 in the Journal of Experimental Medicine, suggests that targeting EZH2 could therefore be an effective treatment for AML, an aggressive blood cancer expected to kill over 10,000 people in the US alone this year. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 19, 2019 Category: Cancer & Oncology Source Type: news

Potential Link Between Industrial Pollutants and Acute Myeloid Leukemia Examined
A recent study evaluated whether living in an industrial city could be an important risk factor for developing AML. (Source: CancerNetwork)
Source: CancerNetwork - March 8, 2019 Category: Cancer & Oncology Authors: John Schieszer Source Type: news

Treosulfan Better Than Busulfan in Prep for HSCT Treosulfan Better Than Busulfan in Prep for HSCT
Older and sicker patients with acute myeloid leukemia undergoing stem cell transplant may fare better if they are given a treosulfan- rather than busulfan-based regimen, German scientists have shown.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 5, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Amgen Highlights Progress Of Innovative Early Oncology Pipeline With New Data At AACR 2019
First Preclinical Data to be Presented on AMG 510, a First-in-Class KRASG12C Inhibitor for Solid Tumors New Preclinical Data Evaluating AMG 757 to Highlight Half-Life Extended BiTE® Immunotherapy AMG 176 Preclinical Data Showcase Potential in Combination With Standard of Care Treatments for Acute Myeloid Leukemia THOUSAND OAKS, Calif., Feb. 28, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that new data from its early-stage oncology pipeline will be presented at the American Association for Cancer Research (AACR) Annual Meeting in Atlanta, March 29 – April 3, 2019. "At Amgen, we ar...
Source: Amgen News Release - February 28, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

An atlas of an aggressive leukemia
(Ludwig Institute for Cancer Research) A team of researchers led by Bradley Bernstein at the Ludwig Center at Harvard has used single-cell technologies and machine learning to create a detailed 'atlas of cell states' for acute myeloid leukemia (AML) that could help improve treatment of the aggressive cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 28, 2019 Category: Cancer & Oncology Source Type: news

Atlas of acute myeloid leukemia cell types may lead to improved, targeted therapies
(Massachusetts General Hospital) A research team led by Massachusetts General Hospital investigators has assembled a detailed atlas of bone marrow cells from patients with acute myeloid leukemia, an aggressive blood cancer that usually leads to death within five years of diagnosis. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 28, 2019 Category: Cancer & Oncology Source Type: news

After two deaths, FDA hits the brakes on leukemia treatment study
The FDA has placed a partial hold on a phase 1 study into the study of a treatment for acute myeloid leukemia (AML). (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - February 20, 2019 Category: Pharmaceuticals Source Type: news

Mother, 35, discovers her cough that wouldn't shift is life-threatening LEUKAEMIA
Louise Moreton, from Melbourne, started feeling run-down after moving to Durham, England, with her husband and their son. She was quickly diagnosed with acute myeloid leukaemia. (Source: the Mail online | Health)
Source: the Mail online | Health - February 18, 2019 Category: Consumer Health News Source Type: news

New therapy for aggressive blood cancer discovered
(University of Veterinary Medicine -- Vienna) Researchers at Vetmeduni Vienna and Ludwig Boltzmann Institute for Cancer Research have identified a new therapeutic strategy for Acute Myeloid Leukemia. They found that the activity of the mutated oncogenic protein C/EBPα is dependent on MLL1 histone methyltransferase complex. Laboratory tests showed that functional perturbation of MLL1 complex led to death of AML cells with C/EBPα mutations. Inhibitor treatment released the differentiation block of cancer cells and restored normal maturation of blood cells. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 13, 2019 Category: International Medicine & Public Health Source Type: news

Role of the ALK Inhibitor AZD3463 in Sorafenib-Resistant Acute Myeloid Leukemia
Investigators evaluated whether  AZD3463 can induce apoptosis in a dose-dependent manner in a subset of AML patients. (Source: CancerNetwork)
Source: CancerNetwork - February 8, 2019 Category: Cancer & Oncology Authors: John Schieszer Source Type: news

Does Chemotherapy Increase the Risks of Myelodysplastic Syndrome and Acute Myeloid Leukemia?
The study, published in JAMA Oncology, examined whether treatment of 22 solid tumor types was associated with two therapy-related conditions. (Source: CancerNetwork)
Source: CancerNetwork - February 7, 2019 Category: Cancer & Oncology Authors: Christina Bennett, MS Source Type: news

Drug compound could be next-generation treatment for aggressive form of leukemia
Researchers have been struggling for years to find a treatment for patients who have a recurrence of acute myeloid leukemia (AML), an aggressive blood cancer that is one of the most lethal cancers. About 19,520 news cases are diagnosed a year, and about 10,670 people a year die from it, according to the American Cancer Society. (Source: World Pharma News)
Source: World Pharma News - January 28, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Drug compound could be next-generation treatment for aggressive form of leukemia
(Purdue University) Purdue University researchers are developing a series of drug compounds that have shown promise in treating acute myeloid leukemia, an aggressive blood cancer that is one of the most lethal cancers. About 19,520 news cases are diagnosed a year, and about 10,670 people a year die from it, according to the American Cancer Society.About 30 percent of AML patients have a mutation caused by a kinase called FLT3, which makes the leukemia more aggressive. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 28, 2019 Category: Cancer & Oncology Source Type: news

WATCH: How one mom turned grief into action
Robin Roberts' highlights the work of a mother who lost her 9-year-old son to acute myeloid leukemia in 2014 and how she is turning her grief into action as part of her "Thriver Thursday" series. (Source: ABC News: Health)
Source: ABC News: Health - January 17, 2019 Category: Consumer Health News Tags: GMA Source Type: news

The Emerging Profile of Immunotherapy Approaches in the Treatment of AML
Dr. Daver discusses immunotherapy approaches for patients with acute myeloid leukemia (AML), and his recent study results on the combination of azacitidine and nivolumab. (Source: CancerNetwork)
Source: CancerNetwork - January 17, 2019 Category: Cancer & Oncology Authors: Naval Daver, MD Source Type: news

Killer blows? Knockout study of pair of mouse MicroRNA provides cancer insight
(Tokyo Medical and Dental University) Tokyo Medical and Dental University (TMDU) researchers used knockout mouse models created by gene editing to reveal that the miRNA miR-146b, like miR-146a, is involved in the development of cancers, with them having similar but not identical effects. The knockout mice showed high rates of B-cell lymphoma and acute myeloid leukemia, which was associated with the absence of miRNA causing NF-κB overactivation. These insights should help in the fight against cancers involving miRNA dysregulation. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - January 17, 2019 Category: Biology Source Type: news

Young dad thanks blood donors who saved his life
As Tyler Bacon gripped the lectern in Carnesale Commons and scanned the crowd gazing at him expectantly, he struggled to hold back tears.The 39-year-old father of two from Thousand Oaks was finally meeting some of the more than two dozen people whose blood and platelet donations sustained his life during cancer treatment at  Ronald Reagan UCLA Medical Center.  “Because you showed up and donated, my parents still have a son,” Bacon said. “My children have a dad. My wife has a husband.”His voice quaking with emotion, he added, “All the gratitude in the world would not be enough to say ...
Source: UCLA Newsroom: Health Sciences - January 17, 2019 Category: Universities & Medical Training Source Type: news

Father of two thanks blood donors who saved his life
As Tyler Bacon gripped the lectern in Carnesale Commons and scanned the crowd gazing at him expectantly, he struggled to hold back tears.The 39-year-old father of two from Thousand Oaks was finally meeting some of the more than two dozen people whose blood and platelet donations sustained his life during cancer treatment at  Ronald Reagan UCLA Medical Center.  “Because you showed up and donated, my parents still have a son,” Bacon said. “My children have a dad. My wife has a husband.”His voice quaking with emotion, he added, “All the gratitude in the world would not be enough to say ...
Source: UCLA Newsroom: Health Sciences - January 16, 2019 Category: Universities & Medical Training Source Type: news

Is the Revised ELN Classification More Accurate for Acute Myeloid Leukemia?
A new study published in Cancer compared ELN-2017 to ELN-2010 in terms of distinguishing prognosis in younger patients with newly diagosed AML. (Source: CancerNetwork)
Source: CancerNetwork - January 14, 2019 Category: Cancer & Oncology Authors: John Schieszer Source Type: news

Myelodysplastic Syndrome/AML Risk Increased After Chemo
FRIDAY, Jan. 4, 2019 -- The risks for therapy-related myelodysplastic syndrome or acute myeloid leukemia (tMDS/AML) are elevated after chemotherapy use for solid tumors, according to a study published online Dec. 20 in JAMA Oncology. Lindsay M.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 4, 2019 Category: Pharmaceuticals Source Type: news

Study finds elevated risk of rare blood cancers after chemotherapy for most solid tumors
(NIH/National Cancer Institute) Findings from a new study by researchers at the National Cancer Institute (NCI) show that patients treated with chemotherapy for most solid tumors during 2000-2014 experienced an increased risk of therapy-related myelodysplastic syndrome/acute myeloid leukemia (tMDS/AML). The study was published December 20, 2018, in JAMA Oncology. NCI is part of the National Institutes of Health. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 20, 2018 Category: Cancer & Oncology Source Type: news

First Hedgehog Pathway Inhibitor Approved in AML Patients
Clinicians now have a new treatment to offer elderly patients with newly diagnosed acute myeloid leukemia who have comorbidities that preclude the use of intensive chemotherapy. (Source: CancerNetwork)
Source: CancerNetwork - December 13, 2018 Category: Cancer & Oncology Authors: John Schieszer Source Type: news

Newly Approved Agent Fills Gap in Therapy for High-Risk AML
The US Food and Drug Administration recently approved a new agent for  treatment of adult patients with relapsed or refractory acute myeloid leukemia. (Source: CancerNetwork)
Source: CancerNetwork - December 13, 2018 Category: Cancer & Oncology Authors: John Schieszer Source Type: news

Can Azacitidine Delay Relapse in MRD-Positive AML?
Azacitidine may delay or prevent relapse among patients with MRD-positive acute myeloid leukemia or myelodysplastic syndrome. (Source: CancerNetwork)
Source: CancerNetwork - December 13, 2018 Category: Cancer & Oncology Authors: Bryant Furlow Source Type: news

Potential seen for tailoring treatment for acute myeloid leukemia
(University of Washington Health Sciences/UW Medicine) Rapid screening of leukemia cells for drug susceptibility and resistance are bringing scientists closer to patient-tailored treatment for acute myeloid leukemia. Research on the differing drug response patterns of leukemia stem cells and blasts may show why some attempts to treat are not successful and why some patients relapse. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 7, 2018 Category: Cancer & Oncology Source Type: news

New Venclexta/Venclyxto data demonstrate deep responses in two of the most common types of leukaemia
Roche today announced new data from the Venclexta ®/Venclyxto® (venetoclax) clinical development programme, including longer-term results from the phase III MURANO study in people with previously treated chronic lymphocytic leukaemia (CLL) and updated data from two phase Ib/II studies in people with previously untreated acute myeloid leukaemia (A ML) ineligible for intensive chemotherapy due to coexisting medical conditions. (Source: Roche Media News)
Source: Roche Media News - December 4, 2018 Category: Pharmaceuticals Source Type: news

New Venclexta/Venclyxto data demonstrate deep responses in two of the most common types of leukaemia
Roche today announced new data from the Venclexta ®/Venclyxto® (venetoclax) clinical development programme, including longer-term results from the phase III MURANO study in people with previously treated chronic lymphocytic leukaemia (CLL) and updated data from two phase Ib/II studies in people with previously untreated acute myeloid leukaemia (A ML) ineligible for intensive chemotherapy due to coexisting medical conditions. (Source: Roche Investor Update)
Source: Roche Investor Update - December 4, 2018 Category: Pharmaceuticals Source Type: news

Amgen Announces First-In-Human Data Evaluating Investigational Novel BiTE ® Immunotherapies AMG 420 And AMG 330 At ASH 2018
Phase 1 Results of Amgen's BiTE® Platform in Heavily Pre-Treated Patients With Multiple Myeloma and Acute Myeloid Leukemia FDA Grants Fast Track Designation for AMG 420 THOUSAND OAKS, Calif., Dec. 3, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the first clinical results from studies evaluating investigational novel bispecific T cell engager (BiTE®) immunotherapies AMG 420 and AMG 330. In two separate Phase 1 dose escalation studies, AMG 420, which targets B-cell maturation antigen (BCMA), and AMG 330, which targets CD33, provided early evidence of tolerability and anti-tumor activity in pat...
Source: Amgen News Release - December 4, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Screening LSCs For AML Drug Resistance, Sensitivity
Researchers used high throughput drug screening on leukemic stem cells to determine drug resistance and sensitivity in acute myeloid leukemia patients. (Source: CancerNetwork)
Source: CancerNetwork - November 30, 2018 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news

Allogeneic Transplantation in Elderly AML Patients
Allogeneic hematopoietic stem cell transplantation could improve outcomes of elderly patients with acute myeloid leukemia. (Source: CancerNetwork)
Source: CancerNetwork - November 30, 2018 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news

FDA Warns About Serious Adverse Effect of AML Drug Enasidenib FDA Warns About Serious Adverse Effect of AML Drug Enasidenib
A life-threatening adverse effect called differentiation syndrome is not being recognized in patients receiving the acute myeloid leukemia drug enasidenib, says the FDA.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 30, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA Warns About Dangerous Side Effect of AML Drug Enasidenib FDA Warns About Dangerous Side Effect of AML Drug Enasidenib
A life-threatening side effect called differentiation syndrome is not being recognized in patients receiving the acute myeloid leukemia drug enasidenib, says the FDA.News Alerts (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 30, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves Treatment for AML Patients With Gene Mutation
THURSDAY, Nov. 29, 2018 -- Xospata (gilteritinib) tablets were approved today by the U.S. Food and Drug Administration for treatment of relapsed or refractory acute myeloid leukemia (AML) in adults with an FLT3 mutation, the agency announced in a... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 29, 2018 Category: Pharmaceuticals Source Type: news

Wendy Atkin obituary
Epidemiologist whose research led to a breakthrough in bowel cancer screening programmes worldwide“Breakthrough” is an overused word when applied to medical advances. But in the case of the2010 trial of a new screening test for bowel cancer led by Wendy Atkin, professor of gastrointestinal epidemiology atImperial College London, who has died of acute myeloid leukaemia aged 71, it is fully deserved. Its impact will be felt by millions. The trial was the first in the world to show that bowel cancer – the second biggest cancer killer in the UK – could be prevented with a simple, five-minute test.The ex...
Source: Guardian Unlimited Science - November 29, 2018 Category: Science Authors: Ara Darzi Tags: Cancer research Health Medical research Science Source Type: news

Venetoclax combination approved for elderly AML
(Dana-Farber Cancer Institute) Older patients with acute myeloid leukemia (AML) often aren't healthy enough to receive intensive chemotherapy, and gentler treatments aren't very effective in treating this aggressive blood cancer.But a new option -- a combination of a standard drug and the novel agent venetoclax -- has been granted accelerated approval by the Food and Drug Administration for such patients after a large, multicenter phase 1 clinical trial showed the combination had 'promising efficacy' and was well tolerated in older AML patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 29, 2018 Category: International Medicine & Public Health Source Type: news

FDA Approves Gilteritinib for FLT3+ Acute Myeloid Leukemia FDA Approves Gilteritinib for FLT3+ Acute Myeloid Leukemia
The FDA's approval is for the first drug targeting FLT3 mutations in AML.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 29, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves Xospata (gilteritinib) for Acute Myeloid Leukemia (AML) with a FLT3 Mutation
November 28, 2018 -- The U.S. Food and Drug Administration today approved Xospata (gilteritinib) tablets for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 28, 2018 Category: Drugs & Pharmacology Source Type: news

FDA approves treatment for adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a certain genetic mutation
The FDA approved Xospata (gilteritinib) tablets for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test. (Source: Food and Drug Administration)
Source: Food and Drug Administration - November 28, 2018 Category: American Health Source Type: news

91 percent response rate for venetoclax against newly diagnosed AML in older adults
Clinical trial results published in the journal Nature Medicine show 91 percent response rate to the combination of venetoclax with azacitidine in older adults newly diagnosed with acute myeloid leukemia (AML). Of 33 patients given combination venetoclax and azacitidine, 20 experienced a complete response (aka complete remission) and eight experienced a complete response but with continued low blood counts. (Source: World Pharma News)
Source: World Pharma News - November 28, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

FDA approves new targeted drug for leukemia tested at University of Pennsylvania
(University of Pennsylvania School of Medicine) The US Food and Drug Administration (FDA) has approved the first ever inhibitor drug specifically approved for treating patients with relapsed or refractory acute myeloid leukemia (AML) with a mutation in the Fms-like tyrosine kinase 3 (FLT3) gene. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 28, 2018 Category: Cancer & Oncology Source Type: news

91 percent response rate for venetoclax against newly diagnosed AML in older adults
(University of Colorado Anschutz Medical Campus) Clinical trial results published in the journal Nature Medicine and being presented this weekend at the American Society for Hematology Annual Meeting show 91 percent response rate to the combination of venetoclax with azacitidine in older adults newly diagnosed with acute myeloid leukemia (AML). Of 33 patients given combination venetoclax and azacitidine, 20 experienced a complete response (aka complete remission) and eight experienced a complete response but with continued low blood counts. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 28, 2018 Category: Cancer & Oncology Source Type: news

FDA Approves New Treatment for Acute Myeloid Leukemia
Randomized clinical trial showed significant improvement in overall survival with Daurismo (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - November 27, 2018 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Geriatrics, Institutional, Source Type: news

Pfizer nabs fourth oncology approval in two months
The FDA has approved Pfizer ’s new drug, Daurismo, for patients with acute myeloid leukemia. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - November 26, 2018 Category: Pharmaceuticals Source Type: news

FDA Approves New Treatment for Acute Myeloid Leukemia
MONDAY, Nov. 26, 2018 -- The U.S. Food and Drug Administration recently announced the approval of Daurismo (glasdegib) tablets for use in combination with a low dose of the chemotherapy cytarabine to treat newly diagnosed acute myeloid leukemia... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 26, 2018 Category: Pharmaceuticals Source Type: news

FDA approves new treatment for patients with acute myeloid leukemia
The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are 75 years of age or older or who have other chronic health conditions or diseases (comorbidities) that may preclude the use of intensive chemotherapy. (Source: World Pharma News)
Source: World Pharma News - November 22, 2018 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Roche announces FDA grants Venclexta accelerated approval for people with newly-diagnosed acute myeloid leukaemia or those who are ineligible for intensive induction chemotherapy
Roche today announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Venclexta ® (venetoclax), in combination with a hypomethylating agent (azacitidine or decitabine), or low dose cytarabine (LDAC), for the treatment of people with newly-diagnosed acute myeloid leukaemia (AML), who are age 75 years or older, or for those ineligible for intensive induction chemotherapy due to coexisting medical conditions. (Source: Roche Media News)
Source: Roche Media News - November 21, 2018 Category: Pharmaceuticals Source Type: news

Roche announces FDA grants Venclexta accelerated approval for people with newly-diagnosed acute myeloid leukaemia or those who are ineligible for intensive induction chemotherapy
Roche today announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Venclexta ® (venetoclax), in combination with a hypomethylating agent (azacitidine or decitabine), or low dose cytarabine (LDAC), for the treatment of people with newly-diagnosed acute myeloid leukaemia (AML), who are age 75 years or older, or for those ineligible for intensive induction chemotherapy due to coexisting medical conditions. (Source: Roche Investor Update)
Source: Roche Investor Update - November 21, 2018 Category: Pharmaceuticals Source Type: news

FDA Approves Daurismo (glasdegib) for Patients with Acute Myeloid Leukemia
November 21, 2018 -- The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for the treatment of newly-diagnosed acute myeloid leukemia... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 21, 2018 Category: Drugs & Pharmacology Source Type: news

FDA approves new treatment for patients with acute myeloid leukemia
The FDA approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are 75 years of age or older or who have other chronic health conditions or diseases (comorbidities) that may preclude the use of intensive chemotherapy. (Source: Food and Drug Administration)
Source: Food and Drug Administration - November 21, 2018 Category: American Health Source Type: news